Skip to main content

Day: August 11, 2020

Cambium Networks Reports Second Quarter 2020 Financial Results

Revenues of $62.3 million, up 3% sequentiallyGross margin of 48.9%, non-GAAP(1) gross margin of 49.2%Net income of $3.3 million or $0.13 per diluted share, non-GAAP(1) net income of $4.3 million or $0.16 per diluted shareAdjusted EBITDA(1) of $7.7 million or 12.3% of revenuesNet cash provided by operating activities $26.2 millionLaunched first in new series of Wi-Fi 6 access points and multi-gigabit enterprise switchesROLLING MEADOWS, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) — Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of wireless networking infrastructure solutions, today announced financial results for the second quarter 2020 ended June 30, 2020.[1]Refer to Supplemental Financial Information accompanying this press release for a reconciliation of GAAP to non-GAAP numbers and for reconciliation...

Continue reading

AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achievedClinically meaningful improvement (>80%) in coefficient of fat absorption (CFA) for all patients across all dose levels of MS1819Topline data from full dataset anticipated in 1Q 2021Management to discuss the interim results on call scheduled for today, August 11, 2020, at 4:30 p.m. Eastern TimeNEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic...

Continue reading

Trevena Announces Proposed Public Offering of Common Stock

CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Trevena intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Guggenheim Securities, LLC is acting as lead book-running manager for the offering.  Cantor Fitzgerald & Co. is also acting as a book-running...

Continue reading

Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $200 million of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Adverum Biotechnologies. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Goldman Sachs & Co. LLC, Cowen and Company, LLC, SVB Leerink LLC and Piper Sandler & Co. are acting...

Continue reading

1st Capital Bank Announces Appointment of Jigisha Desai to Board of Directors

SALINAS, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — 1st Capital Bank (OTC Pink: FISB) today announced the appointment of Jigisha Desai as a director.  Desai is the chief financial officer of Watsonville-based Granite Construction, Incorporated (NYSE: GVA), a nationwide heavy civil construction and transportation contractor. “We are delighted to have Jigisha join our board,” said Kurt Gollnick, chairman.  “She brings a wealth of business and financial experience and a diverse perspective to our board. Her experience with a leading construction and materials firm provides deep insights into the needs of our commercial customers and will be invaluable as we formulate our strategic goals and build the scale of our organization.” Desai will serve on the Bank’s Investment and Asset/Liability Management Committee.Desai joined Granite Construction...

Continue reading

CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results from its Phase 2 COVID-19 Trial

VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Wednesday, August 12, 2020, to provide a comprehensive overview of the compelling results from the Company’s recently completed Phase 2 CD10 trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the...

Continue reading

OLB Group Closes $6.45 Million Public Offering Including Full Exercise of Warrant Overallotment Option

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) — The OLB Group, Inc. (“OLB,” or the “Company”), fintech and payment facilitator, today announced the closing of its previously announced underwritten public offering of 700,000 units consisting of one share of common stock, two Series A warrants, and one half of one Series B warrant. Aegis Capital has fully exercised its option to purchase 210,000 Series A warrants and 52,500 Series B warrants.OLB received gross proceeds of approximately $6.45 million from the offering, before deducting underwriting discount and estimated offering expenses.Aegis Capital Corp. is acting as sole bookrunner for the offering.This offering is being made pursuant to an effective registration statement on Form S-1 (No. 333-232368) previously filed with the U.S. Securities and Exchange Commission (the “SEC”)...

Continue reading

Rapid7 Named a Leader in Midsize Managed Security Services Providers Report from Independent Research Firm

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) — Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced it has been recognized as a Leader in “The Forrester Wave™: Midsize Managed Security Services Providers, Q3 2020” report by Forrester Research Inc. The report also states that the company’s “recent acquisitions improved network analysis and visibility (NAV), making the portfolio comprehensive enough to become a viable alternative to traditional MSSP,” and states that “customers raved about how Rapid7’s dedicated staff provide a huge benefit.”Security teams are continually challenged to do more with less, often struggling to find the time, talent, and technology to elevate their security programs. As a result, organizations are turning to managed security service solutions to help...

Continue reading

Calian Reports Record Third Quarter Results

OTTAWA, Aug. 11, 2020 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX:CGY) today released its quarterly results for the three-month period ended June 30, 2020.Third quarter 2020 highlights:Record quarterly revenue for the eighth consecutive quarterQuarterly revenue of $106 millionAdjusted EBITDA(1) of $9.0 million 75th consecutive profitable quarterNew contract signings of $154 millionDividend of $0.28 per shareCalian (the “Company”) reported revenues for the third quarter of $106 million, representing a 19% increase from the $89 million reported in the same quarter of the previous year.Adjusted EBITDA(1) for the third quarter was $9.0 million, an increase of 34% from $6.7 million in the same quarter of the previous year. Adjusted net profit,(1) which excludes non-cash items related to recent acquisitions, was $5.6 million for the quarter;...

Continue reading

Cartier Closes Private Placement for Total Proceeds of C$9.3M

/ NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES /VAL D’OR, Quebec, Aug. 11, 2020 (GLOBE NEWSWIRE) — Cartier Resources Inc. (TSX-V: ECR) (the “Company” or “Cartier’) announces that it has closed its previously announced private placement (the “Offering”) for aggregate gross proceeds of C$9,364,626. A total of 21,778,200 flow-through common shares of the Company at a price of C$0.43 per share, were issued. The Offering was completed through Paradigm Capital Inc. (the “Agent”).In connection with the Offering, the Agent received a cash fee equal to 6% of the gross proceeds of the Offering and compensation options exercisable to acquire that number of common shares of the Company equal to 6% of the total number of shares issued and sold by the Company pursuant to the Offering, at an exercise...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.